Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENALTY
2023-503520-31-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in progressive multifocal leukoencephalopathy (PML), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Negativation of JCV viral load in the CSF. Planned start Oct 2023; status: authorised.
02
Drugs
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on 2023-503520-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503520-31-00.